Consortium Takes Forian Private at $2.17 Per Share in Healthcare Data Consolidation

A consortium of buyers completed a tender offer for Forian Inc. (NASDAQ: FORA) at $2.17 per share, securing approximately 70% of the healthcare data analytics company and effectively taking it private. The transaction values Forian's equity at roughly $87 million based on the company's 40.1 million shares outstanding as of its last quarterly filing.

Forian accepted the tender offer without naming the consortium members or disclosing the strategic rationale publicly. The $2.17 price represents a 31% premium to the stock's $1.66 closing price on December 13, the last trading day before initial acquisition rumors surfaced in regulatory filings. At 70% ownership, the consortium crosses the threshold typically required to complete a short-form merger under Delaware law, where Forian is incorporated, allowing backend squeeze-out of remaining shareholders without a separate vote.

The acquisition removes one of the smaller independent players in healthcare data infrastructure at a moment when payer and provider systems are consolidating their technology stacks. Forian generated $28.3 million in revenue for the twelve months ending September 2024, down 6% year-over-year, with an adjusted EBITDA loss of $4.1 million. The company's core products—prescription analytics, regulatory intelligence, and scientific data management tools—serve pharmaceutical manufacturers, government agencies, and payer organizations navigating value-based care models and formulary optimization.

Healthcare data M&A has tightened around scale and vertical integration. IQVIA's $1.1 billion acquisition of Whitehat Communications in November and Definitive Healthcare's $140 million take-private in October both reflected buyer preference for platforms with demonstrated profitability or clear paths to margin expansion. Forian's negative EBITDA and declining revenue made organic scaling difficult. The consortium structure suggests financial sponsors or strategic buyers seeking to combine Forian's regulatory data assets with adjacent capabilities, likely in prescription monitoring or Medicare Part D analytics where the company held niche strength.

Allocators tracking healthcare IT should watch for consortium identity disclosure in Forian's upcoming Schedule 14D-9 filing, expected within ten business days. If the buyers include existing data infrastructure platforms, integration announcements and customer migration timelines will follow within 90 days. Minority shareholders holding the remaining 30% can expect a short-form merger or appraisal rights notice within 120 days, at which point the $2.17 price becomes the floor for any dissenting shareholder litigation.

The Forian take-private follows 18 months of sub-$3 trading for a stock that debuted via SPAC merger at $10 in December 2021. The consortium paid 0.9x trailing twelve-month revenue, below the 1.4x median for recent healthcare data acquisitions but consistent with distressed SaaS comps carrying negative EBITDA. No competing bidders emerged during the tender period.